Day 2 Program

Poster Session 1

Day 2: December 9, 2026

12:30 PM–2:00 PM CST

Exhibit Hall

Session Details

P1-1-01

HERTHENA-Breast02: A Phase 1b/2 Study of Patritumab Deruxtecan (HER3-DXd) and Trastuzumab Deruxtecan (T-DXd) in Patients With HR+/HER2-Low or -Ultralow Advanced Breast Cancer After Progression on Endocrine Therapy

Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, TN

P1-1-02

Port-n1 (krog 22-05): a multicenter randomized phase iii noninferiority trial of postoperative radiotherapy de-escalation in patients with pn1 breast cancer

Bum-Sup Jang, Seoul National University Hospital, Seoul, Korea, Republic of

P1-1-03

Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER+ Breast Cancer: A Biomarker-Driven Pilot Clinical Trial

Justine T Hung, University of Wisconsin-Madison, Madison, WI

P1-1-04

Phase 1 study of PRT13722, a first-in-class oral KAT6A-selective degrader, as monotherapy and in combination with fulvestrant, CDK4/6 inhibitor + endocrine therapy, and oral SERD in patients with advanced HR+/HER2- breast cancer

Timothy A Yap, MD Anderson Cancer Center, Houston, TX

P1-1-05

Trial in Progress: Using serial circulating tumor DNA to track tumor burden in patients with metastatic invasive lobular carcinoma of the breast, the multicenter PLUMB Study

Rita Mukhtar, University of California, San Francisco, San Francisco, CA

P1-1-06

An allogeneic, non-gene edited, EGFR-targeted CAR T utilizing a logic-gate to prevent on-target, off-tumor toxicity and mitigate graft-vs-host disease (GVHD): initial data from the DENALI-1 study of A2B395 in advanced solid tumors, including breast cancer

Rebecca A Shatsky, UC San Diego Health's Moores Cancer Center, San Diego, CA

P1-1-07

Neoagora (GEICAM/2023-14): a prospective, multicenter, observational study exploring the clinical utility of serial liquid biopsy (ctDNA) in patients with early-stage breast cancer receiving neoadjuvant therapy

Javier Pascual, Hospital Universitario Virgen de la Victoria, Málaga, Spain; IBIMA, Málaga, Spain; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain

P1-1-08

Brca germline status as predictive biomarker for pcr with pembrolizumab-based neoadjuvant therapy in 153 tnbc patients: a prospective indian cohort study

Nishitha Prashanth, Aster international institute of oncology, Bengaluru, India

P1-1-09

Safe-de (Part B): ctdna-guided chemotherapy selection in patients with stage I HER2-positive and triple-negative breast cancer

Iseult M Browne, The Royal Marsden NHS Foundation Trust, London, United Kingdom

P1-1-10

Weight Intervention with Semaglutide in Patients with Estrogen Receptor-positive breast cancer (WISPER): a randomized, waitlist-controlled feasibility trial of GLP-1 receptor agonist therapy during adjuvant endocrine therapy

Sixten Harborg, Aarhus University Hospital, Aarhus, Denmark

P1-1-11

Preember: a phase 2, open-label study evaluating imlunestrant in premenopausal women with estrogen receptor-positive (er+), her2-negative (her2-) early breast cancer (ebc)

Oleg Gluz, Niederrhein Johanniter Betehsda Mönchengladbach and University Clincis of Cologne, Cologne, Germany

P1-1-12

Emerge-esr1: prospective evaluation of esr1 mutation emergence in routine clinical practice during first-line aromatase inhibitor plus cdk4/6 inhibitor therapy for estrogen receptor-positive, her2-negative advanced breast cancer in spain

Maria Teresa Curiel Garcia, Complejo Hospitalario Universitario Santiago, Santiago de Compostela, Spain

P1-1-13

A Phase I / IIa Trial of Protocol-Directed Active Surveillance for Older Women with Small, Screen-Detected, ER+/HER2- Breast Cancer (ACTIVE)

Neil Carleton, Brigham and Women's Hospital, Boston, MA

P1-1-14

An Open-Label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study

Hannah Linden, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

P1-1-15

Tracking the impact of [18F]fluoroestradiol PET/CT on clinical management of estrogen receptor-positive breast cancer: the FES-TRACK study

Katheryn Santos, Dana-Farber Cancer Institute, Boston, MA

P1-1-16

Circulating tumor DNA guided chemotherapy omission with ribociclib plus endocrine therapy in HR+/HER2- early breast cancer: the RACE trial (trial in progress)

Wenjia Zuo, Fudan University Shanghai Cancer Center, Shanghai, China

P1-1-17

Intermittent Fasting to Improve Breast Cancer Survivorship During Adjuvant Endocrine Therapy: Preliminary Results of a Phase II Feasibility Trial

Sailaja Kamaraju, Medical College of Wisconsin, Milwaukee, WI

P1-1-18

Path-for-young/optima-young: expanding optima to validate multiparameter assay-directed chemotherapy decisions in premenopausal women with er-positive/her2-negative early breast cancer

Ines Vaz-Luis, Gustave Roussy, Villejuif, France

P1-1-19

Phase 1/2 Study of CLIO-8221, a First-in-Class, HER2-targeted, Dual-Payload Exatecan and ATR inhibitor Antibody-Drug Conjugate (ADC) in Patients with Advanced HER2-expressing Solid Tumors

Amita Patnaik, START Center for Cancer Research, San Antonio, TX

P1-1-20

Neoadjuvant sacituzumab govitecan plus pembrolizumab versus standard chemotherapy in stage II-III triple-negative early breast cancer in phase III trial ADAPT-TN-IV

Peter Schmid, Queen Mary University of London, London, United Kingdom

P1-1-21

Pathologic Complete Response (pCR) After Systemic Therapy and Surgery to inform the Optimization of Radiotherapy (PASS-RT)

Shoshana J. Rosenzweig, Memorial Sloan Kettering Cancer Center, New York, NY

P1-1-22

Optiofs: randomized non-inferiority phase ii trial of alternative site goserelin injection for ovarian function suppression in local and locally advanced premenopausal breast cancer

Sarah K. Premji, Sarah Cannon Research Institute, Nashville, TN

P1-1-24

Supersonic001: A randomized phase II trial of neoadjuvant adebrelimab, disitamab vedotin, and carboplatin versus nab-paclitaxel plus carboplatin in HER2-low, hormone receptor-negative breast cancer

Yinduo Zeng, Sun Yat-sen Memorial Hospital, Guangzhou, China

P1-1-25

Polka: a phase 2a, open-label, multi-center study of the DNA polymerase theta inhibitor ART6043 administered orally in combination with olaparib to patients with HER2 negative breast cancer with a germline BRCA1/2 mutation (randomized expansion of study NCT05898399/TBCRC-076)

Mark Robson, Memorial Sloan Kettering, New York, NY

P1-1-26

Impact of pegulicianine on fluorescence guided surgery (pFGS)on radiation therapy treatment options and 5-year local recurrence rates in patients with breast cancer

Kate Smith, Lumicell, Inc, Waltham, MA

P1-1-27

Agatha: a two-stage, single-arm phase ii study of zongertinib plus fulvestrant in participants with hormone receptor-positive/her2-negative advanced breast cancer harboring her2 mutations

Antonio Llombart-Cussac, Hospital Arnau de Vilanova; Medica Scientia Innovation Research (MedSIR), Valencia, Spain

P1-1-28

Elacestrant compared to standard endocrine therapy in biologically high-risk, clinically low-to-intermediate-risk estrogen receptor-positive/HER2-negative early breast cancer in the WSG ADAPTela trial

Peter Schmid, Queen Mary University of London, London, United Kingdom

P1-1-29

A Phase 1b, open-label parallel study evaluating CLR 125 in patients with relapsed or refractory triple negative breast cancer: a trial-in-progress

Pooja Advani, Mayo Clinic Florida, Jacksonville, FL

P1-2-02

Patients with HER2+ breast cancers that are immune+ have extraordinarily high pathologic complete response (pCR) rates to both dual- and single agent anti-HER2 therapy: results from the ISPY2 TRIAL

Denise M Wolf, University of California, San Francisco, San Francisco, CA

P1-2-03

Resolving distinct post-neoadjuvant spatial residual archetypes using LLM-based lexical pathology-radiomic AI/ML models

Julia Dory Ransohoff, Stanford University, Palo Alto, CA

P1-2-04

Serum Autoantibody Signatures in Stage I/II Breast Cancers Among Young Women

Rohan Gnanaolivu, Mayo Clinic, Rochester, MN

P1-2-05

A phase II multicenter study of 18F-Fluorthanatrace PET for primary breast cancer

Lilie L. Lin, University of Texas, MD Anderson Cancer Center, HOUSTON, TX

P1-2-06

Adaptive Translational Rewiring is a Dynamic Biomarker of Chemotherapy-Refractory Triple-Negative Breast Cancer

Jonathan T. Lei, Baylor College of Medicine, Houston, TX

P1-2-07

Risk-adapted ctDNA surveillance in early HER2-positive breast cancer using HER2DX: an individual patient-level simulation analysis

Guillermo Villacampa, Vall d'Hebron Institute of Oncology (VHIO), Barcelona/ SOLTI Cancer Research Group, Barcelona, Spain

P1-2-08

Predictive Role of Tumor-Infiltrating Lymphocytes and PD-L1 in HER2-Positive Early Breast Cancer: Analysis from the Phase III Trial APTneo Michelangelo Trial

Matteo Dugo, IRCCS Ospedale San Raffaele, Milan, Italy

P1-2-09

Evaluating Oncotype DX as a Mediator Between Digital Pathology Deep Learning Models and Breast Cancer Recurrence

Yijia Sun, University of Chicago, Chicago, IL

P1-2-10

Multi-national external validation of a causal multi-modal AI model for prognosis and chemotherapy benefit prediction in HR+/HER2- breast cancer

Francisco J Esteva, Northwell Health, New York, NY

P1-2-11

Immune biomarkers of standard-of-care chemo-immunotherapy response and resistance in early-stage TNBC (TBCRC061)

Andres A. Ocampo, Vanderbilt University Medical Center, Nashville, TN

P1-2-12

Dnmt3a-mutant clonal hematopoiesis as an actionable driver of metastatic awakening in breast cancer

Pablo Sanchez Vela, Memorial Sloan Kettering Cancer Center (MSK) & NYU Grossman School of Medicine (NYU), New York, NY

P1-2-13

Spatially resolved profiling of ADC targets in HR+/HER2- breast cancer: A rational framework for target prioritization

Roberto Buonaiuto, Institute Jules Bordet, Brussels, Belgium

P1-2-14

Cytoplasmic Trop-2 Predicts Sacituzumab Govitecan Uptake and Clinical Benefit in Metastatic Breast Cancer

Daniel S Peiffer, University of Chicago Medicine, Chicago, IL

P1-2-15

Clinical Characterization of Rare Poor‑Prognosis Breast Cancer Subtypes: preliminary results of the GIM34 Rare Study

Chiara Molinelli, University of Genoa, Genoa, Italy

P1-2-16

Tumor specific human leukocyte antigen class I type A protein expression predicts immunotherapy-specific benefit in the TBCRC043 randomized controlled trial of carboplatin ± atezolizumab in metastatic triple-negative breast cancer

Justin M. Balko, Vanderbilt University Medical Center, Nashville, TN

P1-2-17

Patient-centric molecular screening expands access to biomarker-matched therapies in metastatic breast cancer: results from the SOLTI-1903 HOPE study

Raquel Mugeiro Silva, SOLTI Cancer Research Group//Faculty of Sciences, University of Lisbon, Barcelona, Spain

P1-2-18

Molecular residual disease dynamics and the genomic landscape of male breast cancer in a real-world cohort

Sharon H Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-2-19

Baseline plasma cell-free RNA interferon signature identifies immunotherapy resistance in early-stage triple-negative breast cancer

Hunter A. Gaudio, Weill Cornell Medicine, New York, NY

P1-2-20

Added value of ctDNA to MRI- and biopsy-based preRCB algorithm for predicting early-response to neoadjuvant targeted-/chemo-therapy in the I-SPY Platform TRIAL

Denise M Wolf, University of California, San Francisco, San Francisco, CA

P1-2-21

Clinical and Genomic Heterogeneity of First-Line PIK3CA-Mutant HR+/HER2-Negative Metastatic Breast Cancer in REGISTEM study

Ángel Guerrero-Zotano, Instituto Valenciano de Oncología (IVO), Valencia, SPAIN; GEICAM, Madrid, Spain

P1-2-22

Compensatory ovarian endocrine response to giredestrant and antiproliferative activity in premenopausal ER-positive/HER2-negative early breast cancer: translational analyses from the PREcoopERA trial

Elisabetta Munzone, IEO, European Institute of Oncology, IRCCS, Milan, Italy

P1-2-23

Simulation Modeling to Evaluate ctDNA Surveillance Strategies for Node-Negative HR+/HER2- Early Breast Cancer

Oguzhan Alagoz, University of Wisconsin-Madison, Madison, WI

P1-2-24

Distinct Mutational and Immunologic Profiles in HR+/HER2-negative Early-Onset Breast Cancer: Results from a Large Clinico-Genomic Database.

Nerea Lopetegui-Lia, Ohio State University Comprehensive Cancer Center, Columbus, OH

P1-2-25

Multiplex proteomic profiling of pre-treatment tumor samples identifies quantitative HER2, ABCC1, and PDL1 expression as prognostic of outcomes with trastuzumab deruxtecan (T-DXd) in metastatic breast cancer (MBC)

Paolo Tarantino, Dana-Farber Cancer Institute, Boston, MA

P1-2-26

Immune organization beyond lymphocyte abundance defines functional and clinical antitumor immunity in breast cancer

Elia Segui, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain

P1-2-27

Spatial biomarkers of response to radioimmunotherapy in the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

Maxwell Toan Finkelstein, University of North Carolina School of Medicine, Chapel Hill, NC

P1-2-28

Serial circulating tumor DNA (ctDNA) dynamics and kinetics predict time to next treatment in patients with non-measurable estrogen receptor (ER)-positive HER2-negative metastatic invasive lobular carcinoma (mILC)

Jason Mouabbi, UT MD Anderson, Houston, TX

P1-2-29

Early Response Assessment and Differences in Neoadjuvant Therapy Response According to Receptor Subtype and Response Predictive Subtype in the ISPY2 Trial

Amy S. Clark, University of Pennsylvania, Philadelphia, PA

P1-2-30

Tertiary lymphoid structure (TLS) dynamics as early read-out of immunotherapy response in early-stage triple negative breast cancer

Manon de Graaf, Netherlands Cancer Institute, Amsterdam, Netherlands

P1-3-01

Genomic test predicts benefit from paclitaxel versus docetaxel as adjuvant chemotherapy for HR+/HER2- breast cancer: pooled analysis of GEICAM/9906 and PACS-01 trials

Frédérique Penault-Llorca, Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont-Ferrand, France

P1-3-02

Effect of ESR1 Mutations (ESR1m) on Response to Pharmacokinetically (PK) Relevant Doses of SERD-Based Combination (Combo) in ER-Positive (ER+) Breast Cancer (BC)

Adrian Gonzalez, Washington University in St Louis, St Louis, MO

P1-3-03

Breast cancer survivors exhibit DNA methylation alterations spanning multiple hallmarks of aging, with stronger effects among chemotherapy-treated women

Clara Bodelon, American Cancer Society, Atlanta, GA

P1-3-04

Evaluation of Circulating Tumor DNA (ctDNA) from the Phase II TRADE Study of Adjuvant Abemaciclib

Ilana Schlam, Dana-Farber Cancer Institute, Boston, MA

P1-3-05

Clinical Profiles of Breast Cancer Index Minimal Risk Patients from the Netherlands Cancer Registry

Marie-France Jilderda, Leiden University, Leiden, Netherlands

P1-3-06

The AURORA US Prospective Registry (TBCRC): Longitudinal Tissue, Blood, and Image-Based Multiomics of Metastatic Breast Cancer Evolution

Karthik V Giridhar, Mayo Clinic, Rochester, MN

P1-3-07

Development and external validation of a methylation-based ctDNA score for prediction of treatment response and progression-free survival in advanced breast cancer: Results from the plasmaMATCH and PIPA trials

Iseult M Browne, The Institute of Cancer Research, London, United Kingdom

P1-3-08

Longitudinal cfDNA Profiling During Neoadjuvant Chemotherapy for Breast Cancer: Dynamics, Pathological Complete Response, and Relapse-Free Survival — Preliminary Data from the VGH-TAYLOR Study

Chi-cheng Huang, Taipei Veterans General Hospital, Taipei, Taiwan

P1-3-09

The prognostic role of circulatory biomarkers of inflammation in patients with advanced breast cancer treated with antibody drug conjugates

Maria Cirillo, Institut Gustave Roussy, VILLEJUIF, France

P1-3-11

Prevalence and Prognostic Value of ctDNA detection and ESR1 Mutations Across Treatment Lines in HR+/HER2− Metastatic Breast Cancer

Federico Rojo, Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain

P1-3-12

Temporal Dynamics of ESR1Mutations (ESR1m) and Tumor Fraction (TF) During First-Line CDK4/6 Inhibitors (CDK4/6i) Therapy: Tracking Molecular Progression Through Liquid Biopsy

Lorenzo Foffano, Weill Cornell Medicine, New York, NY

P1-3-13

Real-world overall survival with modern systemic therapy in her2-positive breast cancer brain metastases: an integrated clinical, treatment, and imaging analysis

Haruka Itakura, Stanford University, Stanford, CA

P1-3-14

Multiomic circulating tumor DNA profiling to monitor response and resistance to CDK4/6 inhibitors plus endocrine therapy in estrogen receptor-positive metastatic breast cancer

Cristina Molina Gutiérrez, Vall d'Hebron Institute of Oncology, Barcelona, Spain

P1-3-15

Development and validation of a tumor-agnostic 7-gene immune score predictive of ICI-specific benefit and survival in HER2-negative breast cancer

Andres A. Ocampo, Vanderbilt University Medical Center, Nashville, TN

P1-3-16

Distinct Biological Determinants of Antibody-Drug Conjugate Activity in Invasive Lobular Carcinoma

Higinio Dopeso, Memorial Sloan-Kettering Cancer Center, New York, NY

P1-3-17

Integrated multi-omic analysis of advanced lobular breast cancer in the phase 2 ROLo study of crizotinib with or without fulvestrant

Iseult M Browne, The Royal Marsden NHS Foundation Trust, London, United Kingdom

P1-3-19

Precision CDK4/6 Inhibitor Dosing Using Circulating Thymidine Kinase Activity: Real-World Pharmacokinetic-Pharmacodynamic Evidence in HR+/HER2− Metastatic Breast Cancer

Pooja P Advani, Mayo Clinic, Jacksonville, FL

P1-3-20

Implications of Early BCI Testing in ER+ Invasive Breast Cancer

Nimmi Singh Kapoor, University of California Los Angeles, Los Angeles, CA

P1-3-21

The SET<sub>ER/PR</sub> and SET2,3 index as markers of response to neoadjuvant endocrine therapy in ER+/HER2- breast cancer in I-SPY2

Karthik V Giridhar, Mayo Clinic, Rochester, MN

P1-3-22

Real-world adoption of KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer

Jennifer R Rider, ConcertAI, LLC, Cambridge, MA

P1-3-23

Hoxb13 expression in human triple-negative breast cancer is associated with an immunosuppressive tumor microenvironment

Dennis Sgroi, Massachusetts General Hospital, Boston, MA

P1-3-25

Prognostic biomarkers in early onset breast cancers

Ruth Pfeiffer, National Cancer Institute, Bethesda, MD

P1-3-26

Landscape and Clonal Dynamics of Neoantigens Including Non-Canonical Antigens in Breast Cancer: SCRUM-Japan MONSTAR-SCREEN-2

Jun Masuda, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

P1-3-29

Multimodal Profiling Reveals Predictive Biomarkers of Response to Trastuzumab Emtansine in HER2-Positive Breast Cancer

Kang Wang, Karolinska Institutet, Solna, Sweden

P1-3-30

Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed molecular residual disease (MRD) monitoring in breast cancer

Jason A Mouabbi, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-5-01

Comprehensive epigenomic profiling by liquid biopsy identifies biomarkers of response and resistance to PARP Inhibitors (PARPi) and platinum-based therapy in Metastatic Breast Cancer (MBC)

Adela Rodriguez Hernandez, Dana-Farber Cancer Institute, Boston, MA

P1-5-02

Gut microbial-derived acetate associates with chemo-sensitivity in triple-negative early breast cancer

Kirsty Ross, University of Glasgow, Glasgow, United Kingdom

P1-5-03

Circulating Tumor DNA (ctDNA) Dynamics in Early-Stage Triple-Negative Breast Cancer: An early Analysis of the Phase II OCTANE Trial

Mridula George, Rutgers Cancer Institute, New Brunswick, NJ

P1-5-04

Genomic and immunologic landscape of triple-negative breast cancer by age: A comprehensive analysis of over 3,000 patients

Alexis LeVee, UCLA David Geffen School of Medicine, Los Angeles, CA

P1-5-05

Association of Real-Time Serial Circulating Tumor Cell Enumeration With Progression-Free Survival in Patients With Metastatic Breast Cancer

Femke de Snoo, Medex15, Amsterdam, Netherlands

P1-5-06

Clinical outcomes associated with β-blocker use by ADRB2 expression in triple-negative breast cancer (TNBC): A real-world analysis

Kianna J McEwen, Winship Cancer Institute at Emory University, Atlanta, GA

P1-5-07

Infrared fingerprinting of plasma-derived extracellular vesicles discriminates non-metastatic breast cancer from benign breast disease and healthy controls

Juliana Carvalho Penha Pereira, Federal University of Uberlândia, UBERLANDIA/MG, Brazil

P1-5-08

Initial integrated, gene-level, cell-free DNA methylation and fragmentomic profiling in participants of the Northern California Breast Cancer Family Registry

Billy T Lau, Stanford University School of Medicine, Palo Alto, CA

P1-5-09

Breast Cancer Index Demonstrates Improved Prognostic Performance Over CTS5 for Late Distant Recurrence in the TEAM Trial

Karen Taylor, University of Edinburgh, Edinburgh, United Kingdom

P1-5-10

Changes in ctDNA during neoadjuvant chemotherapy (NAC) as a predictor of residual cancer burden (RCB) in inflammatory breast cancer

Megan McClanahan, UT MD Anderson Cancer Center, Houston, TX

P1-5-11

Longitudinal Multiomic Integration Reveals Agent-Specific Predictors and Tumor-Immune Evolution Under Neoadjuvant Therapy in HER2-Positive Breast Cancer

Fei Wang, The second Qiilu hospital of Shandong University, Jinan, China

P1-5-12

Circulating tumor DNA profiling in metastatic breast cancer patients treated with antibody-drug conjugates: A multicenter retrospective analysis

Letizia Pontolillo, Weill Cornell Medicine, New York, NY

P1-5-13

Inter-observer stromal TIL scoring variability and prediction of pembrolizumab benefit in early HER2+ breast cancer: biomarker analysis of the phase II neoHIP trial

Heather L McArthur, UTSW, Dallas, TX

P1-5-14

Fibroblast Growth Factor Receptor 4 (FGFR4) protein expression in HR+/HER2− metastatic breast cancer after CDK4/6 inhibitor progression: prevalence, molecular associations, and therapeutic implications

Francisco Javier Muñoz-Carrillo, Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain

P1-5-15

Tracking transcriptional states and treatment resistance in ER+ metastatic breast cancer using liquid biopsies

David Gallo, UW Madison, Madison, WI

P1-5-16

Efficacy of adjuvant cyclin-dependent kinase 4/6-inhibitors (CDK4/6i) plus endocrine therapy (ET) versus ET alone across breast cancer (BC) PAM50 intrinsic subtypes (IS): pooled analysis of randomized controlled trials (RCTs)

Francesco Schettini, Hospital Clínic de Barcelona, Barcelona, Spain

P1-5-17

Clinical outcomes with trastuzumab deruxtecan (T-DXd) in metastatic breast cancer by level of tumor-infiltrating lymphocytes

Paolo Tarantino, Dana-Farber Cancer Institute, Boston, MA

P1-5-18

Functional Immune Profiling of Ex Vivo Triple-Negative Breast Cancer Tumor Fragments Predicts Checkpoint Inhibitor Response

Pooja P Advani, Mayo Clinic, Jacksonville, FL

P1-5-19

Baseline PBMCs single-cell profiling identifies T-cell states associated with pembrolizumab response in early triple negative breast cancer

Iñaki Comino-Mendez, IBIMA Plataforma BIONAND, Malaga, Spain

P1-5-20

Longitudinal molecular residual disease (MRD) monitoring in patients with stage I breast cancer using a whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) assay

Nour Abuhadra, Memorial Sloan Kettering Cancer Center, New York, NY

P1-5-21

Carboplatin Selectively Benefits Patients with Low Tumor-Infiltrating Lymphocytes and Margin-Restricted Immune Phenotype in Early-Stage TNBC: Translational Findings from the PEARLY Randomized Trial

Yoon Jin Cha, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

P1-5-22

A cis-Regulatory Variant of UACA Drives Chemotherapy Sequence-Dependent Survival in Breast Cancer

Qianqian Zhu, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P1-5-23

Evaluation of a 113-gene taxane response predictor using updated Response Predictive Subtypes in the I-SPY2 cohort

Jan Nart, Aida Oncology, Copenhagen, Denmark

P1-5-24

Circulating Growth Differentiation Factor-15 Predicts Survival Outcomes in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Results from the DESIREE Trial

Marc Antonius Maria Thill, Agaplesion Markus Krankenhaus, Frankfurt, Germany

P1-5-25

Gut microbiome impact on outcome in patients with high-risk triple negative breast cancer (TNBC) randomized to adjuvant avelumab vs observation in the A-BRAVE trial.

Maria Vittoria Dieci, University of Padova; Veneto Institute of Oncology IRCCS, PD, Italy

P1-5-26

Monitoring PD-L1 Upregulation in Circulating Cancer Associated Macrophage-like Cells in Blood Predicts 24 Month Outcomes in Metastatic Triple Negative Breast Cancer Treated with PD-L1/PD-1 Immune Checkpoint Inhibitors

Daniel L Adams, Creatv Microtech, Inc., Monmouth Junction, NJ

P1-5-27

Her2 rna outperforms ihc in predicting outcomes to t-dxd

Joshua SK Bell, Tempus AI, Chicago, IL

P1-5-28

Trop-2 expression and transcriptomic signatures as biomarkers of sacituzumab govitecan efficacy in patients with metastatic breast cancer

Viola Moscarda, European Institute of Oncology IRCSS, Milan, Italy

P1-5-29

Protein Drug Target Analysis Identifies Phosphorylated AKT as a Key Therapeutic Target in MammaPrint H2 tumors from TNBC Patients Destined for Non-Response

Emanuel F Petricoin, George Mason University, Manassas, VA

P1-5-30

Association of Quantitative HER2 mRNA Expression and 21-Gene Assay Recurrence Score with Trastuzumab Deruxtecan Treatment Duration in HER2-Negative Metastatic Breast Cancer

Adriana Kahn, Yale Cancer Center, New Haven, CT

P1-6-01

Prognostic significance of progesterone receptor isoforms in luminal breast cancer

Lucas Lemos, Institute of Biology and Experimental Medicine (IBYME), Buenos Aires, Argentina

P1-6-02

Hormone Receptor and HER2 Stability from ADH to DCIS: Single-Cell Evidence for Receptor Profiling in High-Risk Lesions

Henry Kaplan, Swedish Cancer Institute, Seattle, WA

P1-6-03

Circulating Tumor DNA Versus Conventional Serum Tumor Markers for Prediction of Residual Cancer Burden and Disease-Free Survival in Inflammatory Breast Cancer

Iman Jaka, UT MD Anderson Cancer Center, Houston, TX

P1-6-04

Pik3ca activating mutations are associated with reduced durable clinical benefit following immune checkpoint inhibitor therapy in metastatic triple-negative breast cancer

Neha Verma, Duke University School of Medicine, Durham, NC

P1-6-05

Clinical Validation of an Integrated Breast Cancer Risk Prediction Model in a Real-World Korean Screening Cohort

Tae-Woong Ha, DCGen Co., Ltd., Seoul, Korea, Republic of

P1-6-06

Evaluating Clinically Actionable Somatic and Germline Mutations in Black and NonHispanic White Women with Breast Cancer

Heather Bagley, Myriad Genetics, Salt Lake City, UT

P1-6-07

Tumor-derived DNA in whole-node homogenates reveals distinct dynamics of lymphatic and hematogenous dissemination in breast cancer

Takanori Kin, The University of Osaka Graduate School of Medicine, Osaka, Japan

P1-6-09

Systemic immune biomarkers of breast cancer-related lymphedema and therapeutic lymphovenous bypass response

Alvin Liu, The Ohio State University, Columbus, OH

P1-6-10

Development of a Quantitative Immunohistochemistry Assay as a Tissue Companion Diagnostic for PARP Inhibitor Therapy

Sina Bagheri, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

P1-6-11

The molecular features of low oncotype recurrence score HR+/HER2- breast cancers with latent metastasis – an updated study with 21 cases

Liu Liu, Brown University Health, Warren Alpert Medical School of Brown University, Providence, RI

P1-6-12

Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab in Metastatic Triple Negative Breast Cancer

Zahi Mitri, BC Cancer Vacouver, Vancouver, BC, Canada

P1-6-13

Dynamic Biomarkers of Residual Disease After Neoadjuvant Therapy: Prognostic Impact of Grade Escalation, Persistent High Ki-67, and Biological Subtype Conversion

Katarzyna Pogoda, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

P1-6-14

Sequencing of PARP Inhibitors and Trastuzumab Deruxtecan in BRCA1/2/PALB2-Altered, HER2-Negative Metastatic Breast Cancer: A Retrospective Study from the Nationwide De-Identified Tempus Database

Alexis LeVee, UCLA David Geffen School of Medicine, Los Angeles, CA

P1-6-15

Immune Responses to CTAG1 (NY-ESO-1) is Potential Predictor of Outcome in Triple-Negative Breast Cancer

Nicholas C. Dove, Mayo Clinic, Jacksonville, FL

P1-6-16

Comprehensive validation of peripheral blood inflammatory biomarkers demonstrates no independent predictive value for pathological complete response in triple-negative breast cancer in the pembrolizumab era

Elzbieta Senkus, Medical University of Gdansk, Gdansk, Poland

P1-6-18

Breast Cancer Index provides independent prediction of extended endocrine therapy benefit across clinical risk groups

Ori Kvint, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

P1-6-19

Assay performance and longitudinal quantification using a tissue-free, molecular residual disease assay in breast cancer

Tzu-Chun Chen, Natera, Inc., Austin, TX

P1-6-20

Prognostic validation of the AI-based Stratipath Breast medical device in a US-based study

Kajsa Ledesma Eriksson, Karolinska Institutet, and Stratipath AB, Stockholm, Sweden

P1-6-21

Pathway-guided bayesian consensus clustering for molecular subtyping of invasive lobular carcinoma in SCAN-B and METABRIC cohorts

Steffi Oesterreich, University of Pittsburgh School of Medicine, Pittsburgh, PA

P1-6-22

Association of Initial CT Lobar Extent With Recurrent Interstitial Lung Disease (ILD) After Antibody-Drug Conjugate (ADC) Rechallenge in Metastatic Breast Cancer (MBC)

Thanate Dajsakdipon, European Institute of Oncology, IRCCS, Milan, Italy

P1-6-23

Tumor-infiltrating lymphocytes predict long-term outcome in patients treated with neoadjuvant systemic therapy: Results from the Prospective Randomized ABCSG-34 Trial

Sabine Danzinger, Medical University of Vienna, Vienna, Austria

P1-6-24

Integrated pharmacologic and transcriptomic profiling reveals therapeutic vulnerabilities associated with CDH1 deficiency in invasive lobular carcinoma

Higinio Dopeso, Memorial Sloan-Kettering Cancer Center, New York, NY

P1-6-25

Longitudinal ESR1 and PIK3CA clonal evolution during CDK 4/6 inhibitors plus endocrine therapy: an intermediate analysis of the CANIPE study

Maria Teresa T Curiel Garcia, Santiago de Compostela University Hospital (CHUS), Spain, Santiago de Compostela, Spain

P1-6-26

Mammaprint genomic risk stratification reveals differential endocrine therapy benefit on ipsilateral breast tumor recurrence after accelerated partial breast irradiation

John Wilson, University of South Florida, Tampa, FL

P1-6-28

Pik3ca mutations in metastatic breast cancer: lobular histology and her2 status as novel correlates of prevalence and relapse-specific prognosis

MARIA JOSE ECHARRI, HOSPITAL UNIVERSITARIO SEVERO OCHOA, LEGANES, Spain

P1-6-29

A TROP2-Targeted NIR-II Fluorescent Probe for Intraoperative Navigation and Margin Assessment in Breast Cancer

Pei Li, Yunnan Key Laboratory of Molecular Imaging in Oncology, Kunming, China

P1-4-01

Sequential Activity of Investigational Auristatin-Based Antibody-Drug Conjugates (ADCs) Following Topoisomerase I ADCs and Conventional Microtubule-Targeting Agents in Metastatic Breast Cancer: Experience from a Phase I Program

Fabiola Medina, NEXT ONCOLOGY , Hospital Universitario Quirónsalud Madrid, MADRID, Spain

P1-4-02

Iv-eve: everolimus for injection – toxicological and toxicokinetic evaluation of a novel deciparticle everolimus formulation for breast cancer

Wen-Han Chang, Sapu Bioscience, LLC, San Diego, CA

P1-4-03

Targeting RET with FDA-approved selective inhibitors prevents brain metastasis progression of triple-negative breast cancers

Phi Long Tran, Texas A&M Health Science Center, Houston, TX

P1-4-04

Pembrolizumab (P) plus oral metronomic cyclophosphamide (mC) in PD-L1 and/or TIL-positive chest wall breast cancer (PERICLES): a single-arm phase II trial

Pier Paolo Maria Berton Giachetti, European Institute of Oncology (IEO) IRCCS, Milan, Italy

P1-4-05

Antidepressants as Clinically Repurposable Strategy for Estrogen Receptor Positive Breast Cancer

Prabhakar Pitta Venkata, Greehey Children's Cancer Research Institute, University of Texas Health Sciences Center at San Antonio, San Antonio, TX

P1-4-07

First-in-class oral Rac-Cdc42 inhibitor MBQ-167 in patients with metastatic breast cancer: safety and preliminary efficacy from a first-in-human Phase 1 dose-escalation study

Denise Yardley, Sarah Cannon Research Institute, Nashville, TN

P1-4-08

Non-muscle myosin II is associated with poor prognosis and represents a potential therapeutic target in HER2-positive breast cancer

Wasim Feroz, University of Cincinnati, Cincinnati, OH

P1-4-10

Vrn101099, a her2-selective covalent tyrosine kinase inhibitor, demonstrates combination potential with standard-of-care therapy in metastatic her2-positive breast cancer

Shuang Yin Zhang, Voronoi USA, Waltham, MA

P1-4-11

First-in-class oral KAT6A-selective degrader PRT13722 drives deep and durable tumor regressions as monotherapy and in combination in HR+/HER2- breast cancer models with a differentiated preclinical hematological safety profile

Jack Carter, Prelude Therapeutics Incorporated, Wilmington, DE

P1-4-12

Novel ultrasound ablation combined with immune checkpoint inhibitor therapy for triple negative breast cancer

Suhe Wang, University of Michigan, Ann Arbor, MI

P1-4-13

Preliminary phase 1 results from ORION-1, a phase 1/2 study of AVZO-023 with endocrine therapy and/or AVZO-021 in HR+/HER2- metastatic breast cancer (mBC)

Timothy A Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-4-14

Transcriptomic profiling identifies distinct molecular patterns associated with antiproliferative response to elacestrant (ELA) monotherapy in premenopausal patients with ER+/HER2- early breast cancer (eBC): exploratory analysis from the SOLTI-2104 PREMIÈRE study

Sara P Pérez, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain

P1-4-15

In situ Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC alone or combined with tocilizumab and pembrolizumab in unresectable and metastatic breast cancer: Results from a phase I clinical trial

Fumito Ito, University of Southern California, Los Angeles, CA

P1-4-17

From Startup to Sustainability: The New Reality of Research Site Operations

Sandra L Smith, WCG Clinical, Austin, TX

P1-4-18

Exploratory extended follow-up of the ITACA randomised phase IIb trial: evening alpelisib with fasting and low-carbohydrate guidance versus standard morning dosing in PIK3CA-mutated HR-positive/HER2-negative metastatic breast cancer

Dora Cerina Pavlinovic, University Hospital Split, Split, Croatia

P1-4-19

INCB215543, a highly selective CDK4 inhibitor, drives antitumor activity in HR+/HER2− breast cancer models devoid of CDK6-related hematologic toxicity

Joshua R Hummel, Incyte Corporation, Wilmington, DE

P1-4-20

Therapy-induced and aging-associated senescence create targetable vulnerabilities in ERα positive breast cancer

Lena Batoon, Mayo Clinic, Rochester, MN

P1-4-21

Preclinical Evaluation of (Z)-Endoxifen in Estrogen Receptor-Driven Breast Cancer Models

Sandra Hammer, Atossa Therapeutics Inc., Seattle, WA

P1-4-22

Initial clinical results from the first-in-human phase 1/2 study of SNV4818, a highly mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutated advanced cancers including HR+/HER2− breast cancer

Timothy A Yap, MD Anderson Cancer Center, Houston, TX

P1-4-23

Dig nk trial, arm 1.1: initial safety, clinical, and immune data evaluating gemcitabine plus ex vivo expanded allogenic universal donor, tgfβi natural killer (nk) cells in advanced gd2-expressing breast cancers

Margaret Gatti-Mays, The Ohio State University Comprehensive Cancer Center, Columbus, OH

P1-4-24

Bi-paratopic B7-H3-CAR-T cells to treat metastatic triple negative breast cancer

Giulia Escobar, Massachusetts General Hospital, Boston, MA

P1-7-01

Pb301, a novel oral cdk12 inhibitor, demonstrates broad antitumor activity in genomically annotated breast cancer patient-derived xenografts

Mitchell J Elliott, Yale University, New Haven, CT

P1-7-02

Discovery of ATH-886, a novel, potent and highly selective CCNE1 molecule glue shows robust anti-tumor activities and better safety profile

Feng Zhou, Atheron Therapeutics, Shanghai, China

P1-7-03

Targeting XIAP-mediated survival through Sigma-2 receptor-directed drug delivery in inflammatory breast cancer

Pritha PAI, Medical University of South Carolina, Charleston, SC

P1-7-04

A CRISPRa strategy rescues BRCA1 haploinsufficiency in primary mammary epithelial cells from BRCA1 mutation carriers

Hanyi Zhong, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

P1-7-05

Evaluation of Ingenane Diterpenoids for Basal-Like 2 Triple-Negative Breast Cancer

Pamela Duarte, University of Texas Health San Antonio, San Antonio, TX

P1-7-06

Development of TROP2-Targeting Peptide-Drug Conjugates for Triple-Negative Breast Cancer Therapy

Byungheon Lee, Kyungpook National University, Daegu, Korea, Republic of

P1-7-08

Insights from comprehensive tumor profiling across multiple samples in patients with breast cancer

Sameer Udhane, Abbott, Madison, WI

P1-7-09

Tumor-selective proteasome inhibition in TNBC: FAP-activated Bortezomib prodrugs target cancer stem cells

Wa Xian, Wake Forest University, Charlotte, NC

P1-7-10

Small molecule NSC243928 and its analogs inhibit Histone H3-AuroraB and induce immunogenic cell death in triple negative breast cancer

Geeta Upadhyay, Uniformed Services University of Health Sciences, Bethesda, MD

P1-7-11

First-in-class IAP antagonist targets TNBC cancer stem cells and sensitizes anti-PD-1 therapy in preclinical models

Wa Xian, Wake Forest University, Charlotte, NC

P1-7-13

Macrocyclic Diterpene Esters Cytotoxic Selectivity in BL2 TNBC is Driven by PKC Activation

Sofia C Stanfield, University of the Incarnate Word, San Antonio, TX

P1-7-14

Hex-360, a novel her2-targeted adc incorporating a first-in-class translation inhibitor payload demonstrates activity in trastuzumab-dxd-resistant models supporting a first-in-human clinical trial

Tara Lynn Arvedson, Hexagon Bio, Menlo Park, CA

P1-7-15

From Bench to Brain: SCD1 Inhibition by MTI-301 Targets MUFA-Dependent Tumor Growth and Achieves CNS Anti-Tumor Activity in TNBC

Pooja P Advani, Mayo Clinic, Jacksonville, FL

P1-7-16

Harnessing Innate and Adaptive Immunity with a Ligufalimab-Based Mimotope Vaccine to Co-target HER2 and CD47 in Solid Tumors

Joshua Tobias, Medical Univerity of Vienna, Vienna, Austria

P1-7-17

Characterizing the Interaction Between BL2-Selective Diterpenoids and Microtubule-Targeting Agents in Triple-Negative Breast Cancer

Marelly A Perez, University of the Incarnate Word, San Antonio, TX

P1-7-18

Event-free survival as a trial-level surrogate for overall survival in neoadjuvant early breast cancer: an updated correlation analysis

Júnior Samuel Alonso de Menezes, Universidade Federal da Bahia, Salvador, Brazil

P1-7-19

A Z-selective transdermal endoxifen nanoformulation for breast cancer prevention: preclinical evaluation of skin penetration, mammary bioavailability, and biological activity

Oukseub Lee, Northwestern University Feinberg School of Medicine, Chicago, IL

P1-7-20

Ath-466, a highly potent and selective KAT6A degrader, demonstrates robust anti-tumor activity and displays significant synergy with soc therapy in preclinical studies

Lei Jiang, Atheron Therapeutics, Shanghai, China

P1-7-21

Gdc-0077 suppresses progression and metastasis while enhancing chemosensitivity in pik3ca mutant triple negative breast cancer

Qifeng Yang, qilu hospital of shandong univerisity, Jinan, China

P1-7-22

Treatment-matched integration of patient-derived xenografts and clinical cohorts enables prediction of differential chemotherapy response in triple-negative breast cancer

Jonathan T. Lei, Baylor College of Medicine, Houston, TX

P1-7-23

Atomic Force Microscopy-Based Characterization of Stiffness and Viscoelastic Properties in Inflammatory Breast Cancer Models and Patient Samples

Surbhi Shivhare, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-7-24

Modeling the Impact of BRCA1 and BRCA2 Mutations and Estrogen on Breast Cancer Subtypes Using iPSC-Derived Mammary Organoids

Alyssa Okimoto, UT Health Science Center San Antonio, San Antonio, TX

P1-7-25

Lineage tracing reveals an age-driven luminal-to-basal transition in the mammary gland

Thangarajeswari Mohan, The University of Texas at San Antonio Health Science Center, San Antonio, TX

P1-7-26

Circulating Tumor Cell-Derived Organoids from Triple-Negative and T-DXd-Pretreated Relapsed Breast Cancer Patients as Preclinical Models of Metastatic Disease

Shian-Jiun Shih, Cellentia, Inc., San Carlos, CA

P1-7-27

Dose-escalated FLASH radiotherapy achieves durable tumor control in triple-negative breast cancer patient-derived xenografts

Adel Zaid I Mutahar, Stanford School Of Medicine, Palo Alto, CA

P1-7-28

Translation of a Humanized DNA-Binding Priming Agent to Breast Cancer PDX Models Improves Liquid Biopsy Performance

Julia Amaral, Amplifyer Bio, Cambridge, MA

P1-7-29

Ketogenic Diet Differentially Modulates Tumor Growth, Senescence and Immune Remodeling in Preclinical Models of Triple-Negative Breast Cancer

Agne Baseviciene, Houston Methodist Research Institute, Houston, TX

P1-7-30

Rapid Functional Assessment of Chemotherapy Response Using a Zebrafish Xenograft Platform in Triple-Negative Breast Cancer

Ah Reum Lim, Korea University Ansan Hospital, Ansan, Korea, Republic of

P1-8-01

Ccr7-ccl19/21 expression and functional signaling in inflammatory breast cancer

Surbhi Shivhare, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-8-02

Coordinated E-cadherin/p120/β-catenin patterns in lobular carcinoma and their limited correlation with CDH1 alteration

You-Na Sung, Korea University Anam Hospital, Seoul, Korea, Republic of

P1-8-03

Evaluating the Xpert Breast Cancer STRAT4 assay for rapidly generating biomarkers

Sarah Choi, University of California, San Francisco, San Francisco, CA

P1-8-05

Applying Community Practice Insights to Improve HER2-low and HER2-Ultralow Pathology Reporting: The Development of a Practical Resource Guide

Alexis Weinstein, Paradigm Medical Communications, LLC, Orangeburg, NY

P1-8-06

Mucinous carcinoma of the breast: five unusual cases illustrating morphological similarity and molecular diversity

Liu Liu, Brown University Health, Warren Alpert Medical School of Brown University, Providence, RI

P1-8-07

Clinicopathologic Study of Patients with Mucinous Carcinoma of Breast Treated with Neoadjuvant Chemotherapy

Rachael Nakfoor, Cleveland Clinic, Cleveland, OH

P1-8-08

Two components of receptor-panel reclassification between paired breast cancer specimens: a conventional change versus a broader HER2-zero/low-inclusive change

Jessé Lopes da Silva, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil

P1-8-09

Clinicopathologic and Demographic Correlates of Inflammatory Breast Cancer Across a Quantitative Diagnostic Scoring Spectrum: An Expanded Cohort Analysis

Chloe M Atallah, UT Southwestern Medical Center, Dallas, TX

P1-8-10

A neuroendocrine and metabolic program defines invasive solid papillary carcinoma of the breast: a multi-omics comparison with invasive breast carcinoma of no special type

Yuki Hara, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

P1-8-11

Tumor Necrosis in Treatment-Naïve Invasive Breast Carcinoma: Prevalence, Morphologic Patterns, and Clinicopathologic Associations

Annanya Ganapathy Subramanian, Government Kilpauk Medical College and Hospital, Chennai, India

P1-8-12

Association between cancer-associated fibroblast and fibrotic focus in breast cancer and its clinical significance

JUNHO LEE, Daegu Catholic University, School of Medicine, Daegu, Korea, Republic of

P1-8-13

Quantitative mRNA expression of the ERBB2 gene determined by genomic assay as an alternative to IHC analysis of HER2 negative tumors.

Jacey Mitchell, University of Hawaii, Honolulu, HI

P1-8-14

Standardization of poly(ADP-ribose) polymerase 1 immunohistochemistry for breast cancer: robust performance across clinically relevant fixation conditions

Mahsa Kiani, University of Pennsylvania, Philadelphia, PA

P1-8-15

Her2 evaluation (0, 1+, and 2+) and its changes following an academic intervention in southern (Patagonia) centers compared with a National reference center in Argentina

Federico Waisberg, Instituto Alexander Fleming, Buenos Aires, Argentina

P1-8-16

Clinicopathologic Predictors of Malignancy Upgrade Following Surgical Excision of High-Risk Breast Lesions Diagnosed by Core Needle Biopsy: A Brazilian Public Tertiary Cancer Center Experience

Carolina de Souza Vasconcelos, Hospital Cancer of Pernambuco, Recife, Brazil

P1-8-18

When papillary does not mean indolent: clinicopathologic features of invasive papillary carcinoma of the breast

Yang Hu, Stanford University, Stanford, CA

P1-8-19

Cell-free total nucleic acid profiling of cerebrospinal fluid by targeted next-generation sequencing in breast cancer: yield, pre-analytic correlates, and actionable alterations

Gloria Hopkins Sura, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-8-20

Optimizing Pathology for Accurate HER2-low and HER2-ultralow Breast Cancer Classification: Outcomes from a Longitudinal Education Initiative

Joseph Kim, Q Synthesis LLC, Newtown, PA

P1-8-21

Diagnostic and staging challenges in pleomorphic invasive lobular carcinoma: biopsy-pathology discordance and mri contribution

Yael Berner-Wygoda, Hadassah University Hospital, Jerusalem, Israel

P1-8-22

Compartment-specific expression of platelet-derived growth factor receptor-α and -β in invasive breast carcinoma and their clinicopathological significance

JUNHO LEE, Daegu Catholic University, School of Medicine, Daegu, Korea, Republic of

P1-9-01

Utility of Whole Genome Sequencing in TNBC Expanding Actionability via Whole Genome Resolution

Erin Connolly-Strong, Inocras, San Diego, CA

P1-9-02

Proteomics specifically identifies a C5-PIEZO1⁺ endothelial cell axis mediating immunotherapy resistance in triple-negative breast cancer

Yuzheng Xu, Fudan University Shanghai Cancer Center, Shanghai, China

P1-9-03

Germline mirSNP Signatures of Immune Checkpoint Inhibition in Pregnancy-Associated Breast Cancer

Joanne Weidhaas, UCLA, Los Angeles, CA

P1-9-04

Heterodimerization of HER2 and TROP2 Measured as Proximity in Breast Cancer

Mengni He, Yale University, New Haven, CT

P1-9-05

Longitudinal ctDNA features associated with the evolving metastatic organotropism during first-line endocrine therapy in HR+/HER2- metastatic breast cancer

Elisabetta Molteni, University of Udine, Udine, Italy

P1-9-06

Long-term distant metastasis-free survival with the OncoFREE® multigene assay in 1,771 patients with HR+/HER2− early breast cancer, and an age-specific risk threshold

Sae Byul Lee, University of Ulsan College of Medicine, Asan Medical Cente, Seoul, Korea, Republic of

P1-9-07

Excellent outcome with utility of MammaPrint genomic assay in estrogen receptor-positive HER2-negative patients with node-negative and pN1 breast cancer

Neslihan Cabioglu, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey

P1-9-08

Functional HRD status and efficacy outcomes according to pembrolizumab exposure in early triple-negative breast cancer

Benedetta Pellegrino, University Hospital of Parma, Parma, Italy

P1-9-09

Mechanistic and clinical characterization of serum thymidine kinase activity (TKa) dynamics across giredestrant-based combinations in MORPHEUS-BC

Annie Collier, Genentech, South San Francisco, CA

P1-9-10

Utility of Whole Genome Sequencing in HR+ HER2− Breast Cancer: Unveiling Endocrine-Related and Kinase-Pathway Alterations Beyond the Exome

Erin Connolly-Strong, Inocras, San Diego, CA

P1-9-11

Clinical and pathological characteristics of PIK3CA-mutated early and locally advanced HER2-positive breast cancer: A preliminary analysis of an institutional cohort

Paulina Diaz De Leon Alvarado, National Cancer Institute of Mexico, Mexico City, Mexico

P1-9-12

Characterization of Microbiome-Breast Cancer Interactions in Women Undergoing Mastectomy with Immediate Implant-Based Breast Reconstruction

Michael Choi, University of California, San Francisco, San Francisco, CA

P1-9-13

Bridging the Implementation Gap Between Genomic Recommendations and Treatment Delivery in Breast Cancer: A Nationwide Real-World Study of 9,608 Patients Under Universal Health Coverage

Hiroshi Tada, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan

P1-9-14

Baseline lymphocyte count and lymphocyte-derived inflammatory biomarkers are associated with outcome during antibody-drug conjugate therapy for metastatic breast cancer

Christine Deutschmann, Medical University of Vienna, Vienna, Austria

P1-9-15

Longitudinal ctDNA analysis for metastatic recurrence monitoring in low-risk HR+/HER2− early breast cancer

Dae-Won Lee, Memorial Sloan Kettering Cancer Center, New York, NY

P1-9-16

Evaluating liquid biomarkers integrating fibrotic and immune components of the tumor microenvironment in patients with triple negative breast cancer treated with ladiratuzumab vedotin-based therapy

Nicholas Willumsen, Nordic Bioscience, Herlev, Denmark

P1-9-17

Patient-tissue proteogenomics identifies a novel cell-surface tumor antigen as a treatment-retained ADC target in breast cancer

Stephanie Williams, Caris Life Sciences, Tempe, AZ

P1-9-18

Baseline Gut Microbiota in Women with Newly Diagnosed Breast Cancer Across Different Molecular Subtypes: Results from the “BioBreast” Case-Control Study

Diogo Alpuim Costa, Hospital de Cascais, Cascais, Portugal

P1-9-19

Real-world clinical outcomes and molecular landscape of PIK3CA-mutant and PIK3CA-wild-type HR+/HER2− metastatic breast cancer

Jimmitti Teysir, Memorial Sloan Kettering Cancer Center, New York City, NY

P1-9-20

Dynamic changes in circulating cancer stem cells complement baseline circulating epithelial tumor cell enumeration for relapse risk assessment in breast cancer

Monika Pizon, Laboratory Pachmann, Bayreuth, Germany

P1-9-21

Extracellular vesicle-derived miRNA signature for breast cancer detection in BRCA1/2 mutation carriers: the EXO-BRCA study

Angela Toss, University of Modena and Reggio Emilia, Modena, Italy

P1-9-22

Germline BRCA Mutations Drive Circadian-Immune-Repair Reprogramming in Breast Cancer

Ecem Kalemoglu, RUTGERS- Jersey City Medical Center, Jersey City, NJ

P1-9-23

Immune Biomarkers Predict Pathologic Complete Response to Neoadjuvant Therapy in Early TNBC

Olivia Rieur, Mass General Cancer Center/Harvard Medical School, Boston, MA

P1-9-24

Comparative Performance of Tumor Fraction (TF) and Maximum Variant Allele Frequency (VAF) Dynamics for Predicting Radiologic Response in Metastatic Breast Cancer (MBC)

Lorenzo Foffano, Weill Cornell Medicine, New York, NY

P1-9-25

Longitudinal quantitative and qualitative profiling of circulating extracellular vesicles as biomarkers of response to neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer

Timothé Guinel, Institut de Cancerologie de L'ouest, Saint-Herblain, France

P1-9-26

Ultra-sensitive, liquid-only comprehensive genomic profiling detects low allele-fraction ESR1 mutations in a large breast cancer cohort: prevalence, characterization, and implications for therapy

Lenny K Hong, BillionToOne, Menlo Park, CA

P1-9-27

Caloric Restriction for Oncology Research (CAREFOR): Precision Medicine Driving Precision Nutrition in Neoadjuvant Breast Cancer Treatment

LaToya Natalie McLean, Sidney Kimmel Comprehensive Cancer Center, philadelphia, PA

P1-9-28

Suz12-low invasive lobular carcinoma defines a receptor-subtype-independent molecular subgroup: a real-world multimodal analysis

Batul Al-Zubeidy, University of Southern California, Los Angeles, CA

P1-9-29

Baseline fecal metagenomic taxonomy and metabolic pathway profiles associate with pathologic complete response in neoadjuvant chemo- and immunotherapy-treated triple-negative breast cancer

Borbala Szekely, National Institute of Oncology, Budapest, Hungary

P1-9-30

Association between expression of cancer stem cell-associated molecule CD44v9 and the efficacy of neoadjuvant chemotherapy and prognosis in patients with breast cancer

Shoko Yao, University of Fukui, Eiheiji-cho, Yoshida-gun, Fukui, Japan

P1-10-01

Advancing Multidisciplinary Collaboration for Therapy-Induced Hyperglycemia: A Quality Improvement Initiative to Optimize PI3K/AKT Inhibitor Tolerability

Manali Bhave, Emory University School of Medicine, Atlanta, GA

P1-10-02

Impact of Chemotherapy Sequence on Patient-Reported Outcomes During Neoadjuvant KEYNOTE-522 regimen for Stage II-III Triple Negative Breast Cancer

Nili Modi, Henry Ford Health, Detroit, MI

P1-10-03

The Impact of Aromatase Inhibitor Use on GLP-1 Receptor Agonist-Associated Weight Loss in Breast Cancer Survivors

Keri M Cronin, mt sinai west, New York, NY

P1-10-04

Acupuncture and compression for the prevention of peripheral neuropathy induced by taxane-based chemotherapy in breast cancer patients: A randomized controlled trial

Jieqiong Liu, Sun Yat-sen Memorial Hospital, Guangzhou, China

P1-10-05

Glp-1 receptor agonists versus dpp-4 inhibitors in patients with metastatic breast cancer and type 2 diabetes mellitus: a propensity-matched real-world analysis

Anna Homeniuk, UPMC Central PA, Harrisburg, PA

P1-10-06

Clinical and Dose-Related Factors Associated With Recurrent Interstitial Lung Disease (ILD) Following Antibody-Drug Conjugate (ADC) Re-exposure in Metastatic Breast Cancer (MBC)

Thanate Dajsakdipon, European Institute of Oncology, IRCCS, Milan, Italy

P1-10-07

Gabapentinoid Use and Aromatase Inhibitor Prescription Continuation Among Breast Cancer Patients With Musculoskeletal Symptoms: A Multicenter Real-World Analysis

Anna Homeniuk, UPMC Central PA, Harrisburg, PA

P1-10-08

Real-world Inpatient Outcomes of Interstitial Lung Disease in Breast Cancer Hospitalizations

Jennifer Hsu, Brown University, Providence, RI

P1-10-10

Weighing the trade-offs: glp-1 receptor agonists and persistent alopecia in breast cancer patients undergoing chemotherapy

Daniela Urueta Portillo, UTHSCSA, San Antonio, TX

P1-10-11

Patterns of taxane-induced peripheral neuropathy among patients with breast cancer

Armaan Jamal, University of Chicago, Chicago, IL

P1-10-12

Baseline NAFLD/MASLD and Hepatic and Metabolic Outcomes Among Patients With Breast Cancer Receiving Aromatase Inhibitors: A Real-World Propensity-Matched Analysis

Anna Homeniuk, UPMC Central PA, Harrisburg, PA

P1-10-13

Complete safety data from a randomized phase II trial of three preventive anti-diarrheal strategies in patients (pts) with HER2+/HR+ early breast cancer (EBC) receiving extended adjuvant neratinib (DIANER GEICAM/2018-06)

Isabel Blancas, Hospital Universitario Clínico San Cecilio, Granada, Spain; Department of Medicine, Universidad de Granada, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain

P1-10-14

Treatment discontinuation due to adverse events with antibody-drug conjugates in patients with breast cancer: A network meta-analysis

Arman M Niknafs, University of California Los Angeles, Los Angeles, CA

P1-10-15

Frequency, Severity, and daily-life Interference Are Non-Interchangeable Symptom Dimensions Across Endocrine Therapies in HR+ Breast Cancer: A Real-World PRO-CTCAE Study of 3,110 Patients

Aude Guillou, Resilience, Paris, France

P1-10-16

Adverse event profiles of next-generation endocrine therapies in HR+ metastatic breast cancer: a systematic review and meta-analysis

Thiti Susiriwatananont, Mayo Clinic Florida, Jacksonville, FL

P1-10-17

Long-term complications of adjuvant endocrne therapy in young breast cancer survivors; A nationwide cohort study form the Korean National Health Insurance databse following the ASTRRA trial (POST-ASTRRA)

Eunju Shin, Kyunghee university hospital at Gangdong, Seoul, Korea, Republic of

P1-10-18

Balancing Efficacy and Tolerability: A Retrospective Analysis of Carboplatin Dosing (AUC 5 vs AUC 6) in Neoadjuvant TCHP for HER2-Positive Breast Cancer

Ravand Samaeekia, University of California – Irvine (UCI), Orange, CA

P1-10-19

Leveraging Large Language Models to Characterize Menopausal Symptom Management in Early HR+/HER2- Breast Cancer: A Real-World EHR Study

Cleo A. Ryals, Flatiron Health, New York, NY

P1-10-20

Oral mucositis and ocular surface toxicity with datopotamab deruxtecan in breast cancer: a comparative meta-analysis against non small cell lung cancer.

Shreya Ghanshyam Patel, Lakeland Regional Health, Lakeland, FL

P1-10-21

Phase III randomized trial of antisecretory factor for prevention of abemaciclib-induced diarrhea in early breast cancer

Henrik Lindman, Uppsala University Hospital, Uppsala, Sweden

P1-10-22

Safety and Treatment Patterns of Ribociclib plus Endocrine Therapy in Chinese Patients with HR+/HER2− Early Breast Cancer: A Multicenter Prospective Real-World Study with Exploratory Pharmacogenomic Analysis

Chao Ni, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

P1-10-23

Four daily-trajectory phenotypes of pyrotinib-associated diarrhea in HER2-positive breast cancer: natural history, early identification, and the effect of antidiarrheal prophylaxis

Xiaohong Lyu, Peking Union Medical College Hospital, Beijing, China

P1-10-24

Longitudinal Evaluation of Radiological Features and Blood Biomarkers in Breast Cancer Patients with Drug-Induced Interstitial Lung Disease (DIILD): A Retrospective Mayo Clinic Cohort (2018-2023)

Leticia Assad Maia Sandoval, Mayo Clinic, Phoenix, AZ

P1-10-25

Predictors of osteoporosis prior to and after breast cancer

Ishaan Jathal, Mayo Clinic, Rochester, MN

P1-10-26

Longitudinal Analysis of Circulating Cytokines and Inflammatory Gene Expression Patterns in Early-Stage TNBC Patients with Pembrolizumab-Associated irAEs

Jasmin Hundal, Emory University, Atlanta, GA

P1-10-27

Beyond Chronological Age: IgG-Based Biological Age Predicts Cardiotoxicity Risk in Breast Cancer Chemotherapy

Pooja P Advani, Mayo Clinic, Jacksonville, FL

P1-10-28

Safety and Quality-of-Life Outcomes of Transdermal Testosterone in Hormone Receptor-Positive Breast Cancer Patients Receiving Aromatase Inhibitors: A Single-Center Retrospective Study

Camila Castro, Beneficência Portuguesa de São Paulo, Sao Paulo, Brazil

P1-10-29

Glucagon Like Peptide 1 receptor agonists and risk for breast cancer related lymphedema

Sara Myers, The Ohio State University, Columbus, OH

P1-10-30

Cutaneous adverse events on capivasertib with breast cancer: A cohort study on treatment-related toxicity

Ruhi Kanwar, Brigham and Women's Hospital, Boston, MA

P1-11-01

Characterization of inavolisib-associated hyperglycemia in hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Sherry Shen, Memorial Sloan Kettering Cancer Center, New York, NY

P1-11-02

Comparison of breast toxicity according to treatment position after moderate- or ultra-dose hypofractionated radiotherapy

Josiah Nieto, University of Michigan, Ann Arbor, MI

P1-11-03

Distinct Risk Profiles of Heart Failure and Non-Heart Failure Major Adverse Cardiovascular Events among Patients with Early Breast Cancer: A Competing-Risk Analysis

Hideo Shigematsu, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

P1-11-04

Improving Patient-Centered Care in HER2-Directed Antibody-Drug Conjugate (ADC) Management: Results of an Implementation Science Study

Nancy Chan, NYU Langone's Perlmutter Cancer Center, New York, NY

P1-11-05

Potential over admission of low-risk febrile neutropenia among breast cancer patients receiving chemotherapy: A real-world experience from a tertiary cancer center

Sarah Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P1-11-06

Effect of Monosodium Glutamate on Hyposalivation in Patients with Breast Cancer Undergoing Chemotherapy

Mariana Simões do Couto Rosa, Ajinomoto do Brasil, São Paulo, Brazil

P1-11-07

Real-world adverse drug reactions in breast cancer: evidence from a brazilian pharmacovigilance program

Mayara Cristina Oliveira Ortiz, Federal University of Minas Gerais, Belo Horizonte, Brazil

P1-11-08

A Quality Improvement Initiative to Mitigate Immunotherapy-Related Toxicities among Patients Receiving Immunotherapy using a Novel Grade 2 Toxicity Screening tool

Aaron Catalan, Windsor Regional Hospital, Windsor, ON, ON, Canada

P1-11-09

Concurrent selective estrogen receptor modulator and hormone therapy use is not associated with increased venous thrombosis risk in high-risk women: a real-world analysis

Madugodaralalage Gunaratne, Mayo Clinic, Rochester, MN

P1-11-10

Beyond RECIST: early opioid de-escalation captures patient-centered benefit from sacituzumab govitecan in symptomatic advanced breast cancer

Lucrezia Raimondi, Ospedale degli Infermi, Biella, Italy

P1-11-11

Eliminating Biological Variability: A Within-Patient Comparison of Conventional and Hypofractionated Breast Radiotherapy

Adeel Riaz, Rutgers Cancer Institute, New Brunswick, NJ

P1-11-12

Comparative Adverse Event Profiles among PI3K and AKT Inhibitors in Breast Cancer: Meta-Analysis of Phase II and III clinical trials

Katelynn Tran, California University of Science and Medicine, Colton, CA

P1-11-13

Hypersensitivity Reporting Patterns of Five Anti-HER2 Agents: A Real-World Analysis

Tianyi Qian, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China

P1-11-14

Navigate-bc: digital navigation to improve symptom management, treatment adherence, and clinical efficiency during oral cdk4/6 therapy

Laurie M Connors, University of South Florida, Tampa, FL

P1-11-15

Temporal trends and patterns of prevalent type 2 diabetes and metformin use among breast cancer patients 1995-2022

Yuehan Wang, National Cancer Institute, Rockville, MD

P1-11-16

Delirium as a Marker of Inpatient Deterioration Among Older Women Hospitalized With Breast Cancer, 2016-2023

Audrey Efendi, Comprehensive Cancer Centers of Nevada, Central Valley, Las Vegas, NV

P1-11-17

Prior Thoracic Radiotherapy and Sequential Trastuzumab Deruxtecan/SacituzumabGovitecan Exposure as Risk Factors for Interstitial Lung Disease in Metastatic Breast Cancer

Elizabeth dos Santos, AC Camargo Cancer Center, São Paulo, Brazil

P1-11-18

Risk Factors for Ribociclib-Associated Hepatotoxicity in Breast Cancer

Chahat Rana, University of Texas Southwestern Medical Center, Dallas, TX

P1-11-19

Efficacy and Safety of Hetrombopag for Cancer Therapy Induced Thrombocytopenia in Patients with Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Study

Hanfang Jiang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China

P1-11-20

Incidence, severity, and risk factors for interstitial lung disease/pneumonitis with HER2-directed antibody-drug conjugates: a systematic review and meta-analysis

Elias Tayar, HCA Healthcare Clear Lake, Webster, TX

P1-11-21

Investigation of Ethnic Variability in PI3K/AKT Inhibitor-Associated Skin Toxicity Using Human in vitro Keratinocyte and Skin Explant Cultures

Reva Basho, Ellison Medical Institute, Los Angeles, CA

P1-11-22

Impact of Subareolar Gland Transection on Nipple Sensation and Quality of Life After Breast Conserving Surgery

Shiyu Liang, West China Hospital, Sichuan University, Chengdu, China

P1-11-23

Endocrine therapy-associated musculoskeletal symptoms (ETAMS) with next-generation endocrine therapies in HR-positive metastatic breast cancer: a systematic review and meta-analysis

Thiti Susiriwatananont, Mayo Clinic Florida, Jacksonville, FL

P1-11-24

Pembrolizumab‑Associated Immune‑Related Adverse Events in Breast Cancer: A Systematic Review with Meta‑Analysis

Laura B Amin, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-11-25

It's hard to look in the mirror and not see my feminine features": patient perceptions of loss of femininity after breast cancer therapy

Dame Idossa, Mayo Clinic, Rochester, MN

P1-11-26

Rapid-onset serum creatinine increase with CDK4/6 inhibitors reflects tubular transporter inhibition, not true renal decline

Cedric Van Marcke, Cliniques universitaires Saint-Luc, Brussels, Belgium

P1-13-01

Neoadjuvant Response in ASCO/CAP HER2 ISH Group 3 Early-Stage Breast Cancer: A Single-Institution Retrospective Analysis

Alexandra Bili Newman, MD Anderson Cancer Center, Houston, TX

P1-13-02

Late recurrence in patients with HER2-positive breast cancer.

Josephine Van Cauwenberge, Catholic University of Leuven, Leuven, Belgium

P1-13-03

Causal AI-guided individualized allocation of neoadjuvant anti-HER2 targeted therapies for HER2-positive breast cancer

Ding Ma, Fudan University Shanghai Cancer Center, Shanghai, China

P1-13-04

Menopausal status and outcomes after pathologic complete response to neoadjuvant dual HER2 blockade: A PEARL-HER2 LATAM subanalysis

Camila Bobato Lara Gismondi, Hospital Israelita Albert Einstein, São Paulo, Brazil

P1-13-05

Real-world treatment patterns and effectiveness in patients with HER2+ early breast cancer using the EVOLVE registry

Norah Lynn Henry, University of Michigan Rogel Cancer Center, Ann Arbor, MI

P1-13-06

Real-world cardiotoxicity surveillance patterns, incidence, and clinical outcomes among early-stage breast cancer patients receiving curative-intent anti-HER2 therapy

Victoria Piurowski, Providence Portland Medical Center, Portland, OR

P1-13-07

Machine Learning-Guided Transcriptomics Identifies PTP4A-Axis Inhibition as a TKI-Sensitizing Combination Strategy in HER2-Positive Breast Cancer, Successfully Validated In Vitro: Results from I-SPY2

Kingsley V Chow, University of California, San Francisco, San Francisco, CA

P1-13-08

Network meta-analysis (NMA) comparing the efficacy of trastuzumab deruxtecan followed by paclitaxel, trastuzumab, pertuzumab (T-DXd-THP) with taxane, carboplatin, trastuzumab and pertuzumab (TCHP) in the neoadjuvant setting for HER2+ early breast cancer (eBC)

Maki Inoue-Choi, AstraZeneca, Gaithersburg, MD

P1-13-09

Endocrine therapy omission in endocrine-low HER2-positive early-stage breast cancer after neoadjuvant therapy

Mohamad Abdelkhalik, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P1-13-10

Plasma β-Hydroxybutyrate Enhances Anti-HER2 ADC Efficacy in HER2-Positive Breast Cancer through β-Hydroxybutyrylation

Yuwei Li, Fudan University Shanghai Cancer center, Shanghai, China

P1-13-12

Real-world outcomes of sequential neratinib following trastuzumab emtansine vs trastuzumab emtansine alone in patients with residual human epidermal growth factor receptor 2-positive early breast cancer after neoadjuvant therapy: A cohort study from Taiwan

Meng-Xia Su, China Medical University Hospital, Taichung, Taiwan

P1-13-13

Treatment Patterns and Long-Term Outcomes in pathologic T1a-b Node Negative HER2-Positive Breast Cancer

Elyse Rose Lopez, University of Texas MD Anderson Cancer Center, Houston, TX

P1-13-15

Outcomes of HER-2 positive early-stage breast cancer among Li-Fraumeni Syndrome patients: A case-control analysis

Raissa Kentsa, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-13-16

Event-free survival (EFS) and patient reported outcomes (PROs) with neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs. paclitaxel/trastuzumab/pertuzumab (THP) in patients with HER2+ early breast cancer (EBC): results from the randomized phase II MARGOT trial/TBCRC052

Michelle Li, Dana-Farber Cancer Institute, Boston, MA

P1-13-17

An updated look at IBC: Is it all the same?

Kerilyn St. Pierre, University of Tennessee Nashville, Nashville, TN

P1-13-18

Trastuzumab cardiomyopathy therapeutic intervention with carvedilol (tactic) trial

Kathryn J Ruddy, Mayo Clinic, Rochester, MN

P1-13-19

Adjuvant therapies in HER2-positive early breast cancer without pathological complete response after neoadjuvant therapy: a systematic review and network meta-analysis

Peifen Fu, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

P1-13-20

Real-world her2+ early breast cancer treated with dual anti-her2 neoadjuvant blockade: formal eligibility for destiny-breast11 and destiny-breast05 and estimated absolute benefit of trastuzumab deruxtecan in a brazilian cancer center cohort

Monique Tavares, AC Camargo Cancer Center, São Paulo, Brazil

P1-13-21

Efficacy and safety of neoadjuvant T-Bren with or without pertuzumab in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II/III trial

Xiyu Liu, Fudan University Shanghai Cancer Center, Shanghai, China

P1-13-22

Adjuvant trastuzumab across pT1mi, pT1a, and pT1b node-negative HER2-positive breast cancer: outcomes and implications for size-based de-escalation

Ki Beom Kim, Samsung Medical Center, Seoul, Korea, Republic of

P1-13-23

Routine pathology markers approximate RNA-defined Luminal versus HER2-enriched subtype in ER-positive/HER2-positive breast cancer

Emmanouil G Sifakis, Karolinska Institutet, Solna, Sweden

P1-13-25

Adjuvant trastuzumab emtansine (T-DM1) in patients with HER2-positive early breast cancer: updated results from a retrospective, single-center, real-world analysis.

Julian David Etessami, European Institute of Oncology, Milan, Italy

P1-13-26

Real-world pathologic complete response by neoadjuvant regimen and DESTINY-Breast11 eligibility in patients with HER2-positive early breast cancer

Bianca Malagutti, European Institute of Oncology, IRCCS, Milano, Italy

P1-13-27

Optimizing Trastuzumab Deruxtecan Use in Early HER2-Positive Breast Cancer: A Real-World Comparative Modeling Study of Neoadjuvant and Adjuvant Treatment Strategies

Marina Sanches Montemor, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil

P1-13-28

De-escalationg anti-HER2 therapy after pathologic complete response: Outcomes of adjuvant trastuzumab and with or without pertuzumab following neoadjuvant TCHP in HER2-positive breast cancer

Eunju Shin, Kyunhee University Hospital at Gangdong, Seoul, Korea, Republic of

P1-13-29

Efficacy and safety of post-neoadjuvant trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T‑DM1) in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (eBC) from DESTINY-Breast05 by hormone receptor (HR) and operability status

Jame Abraham, Cleveland Clinic, Cleveland, OH

P1-14-01

Comparative effectiveness of taxane, carboplatin, trastuzumab and pertuzumab (TCHP), and doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab and pertuzumab (AC-THP) in real-world US patients (pts) with high-risk HER2+ early breast cancer (eBC)

Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, NY

P1-14-03

Neoadjuvant Trastuzumab Rezetecan and Pertuzumab in HER2-Positive Early Breast Cancer: Primary Results of the HELEN-HER 027 Study

Zhenzhen Liu, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

P1-14-04

Prognostic Value of Pre-treatment Clinical Stage After Pathologic Complete Response in HER2-positive Early Breast Cancer: A Nationwide Real-World Cohort from the Taiwan Cancer Registry

Tsung-Yen Hsieh, Taipei Veterans General Hospital, Taipei, Taiwan

P1-14-05

Cancer-associated Fibroblast Remodeling Following Chemotherapy-Free HER2-Targeted Immunotherapy in Early-Stage, HER2-Enriched Breast Cancer

Nabeeha Qazi, Houston Methodist Research Institute, Houston, TX

P1-14-06

Prognostic and Clinical Role of Blood-Based Liquid Biopsy Biomarkers in Early-Stage HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis

Danielle Fox, McGill University, Montreal, QC, Canada

P1-14-07

Treatment patterns and long-term outcomes in stage I HER2-positive breast cancer: a multicenter real-world cohort

Marcela Jurioli Folquito, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

P1-14-08

Prognostic Significance of TAO Kinase Family Members in ER-Positive/HER2-Negative Breast Cancer Receiving Endocrine Therapy

Ahmed H. Al Sharie, Southeast Health, Dothan, AL

P1-14-09

Progesterone receptor-negative status is associated with increased breast cancer-specific mortality in node-negative invasive lobular carcinoma with favorable clinicopathologic features

Noor Khalid, Simmons Cancer Center, Southern Illinois University School of Medicine, Springfield, IL

P1-14-10

Real-world treatment patterns, safety, and effectiveness of extended adjuvant neratinib in HER2-positive early breast cancer in China: final analysis of the NER-Tree study

Jin Zhang, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

P1-14-11

Cycle 1 Dose Reductions in Early-Stage HER2 Positive Breast Cancer Patients Receiving Docetaxel/Carboplatin (TC): A Real-World Multi-Site Cohort Analysis

Mary C. Schroeder, University of Iowa, Iowa city, IA

P1-14-12

Perceptions, attitudes, and behaviors towards the risk of disease recurrence among patients with HER2-positive early-stage breast cancer in China: Results from the ASKHER2-China survey

Lichen Tang, Fudan University Shanghai Cancer Center, Shanghai, China

P1-14-13

Es2b‑C001 induces anti‑her2 immune responses in patients with advanced her2‑positive and her2‑low breast cancer: preliminary results from an ongoing phase 1 study

Erik Heegaard, ExpreS2ion Biotechnology, Hørsholm, Denmark

P1-14-14

A Network Meta-Analysis of Next-Generation Oral SERDs and PROTACs in ESR1-Mutated Advanced Breast Cancer

Pakeeza Saif, HCA Houston Healthcare Clearlake, Webster, TX

P1-14-15

Evaluating the impact of dose escalation on mitigating neratinib (NER)-related diarrhea in patients (pts) with HER2+/HR+ early breast cancer (EBC): Safety data from the DIANER, CONTROL, and ExteNET trials

Ruiz Borrego Ruiz Borrego, Hospital Universitario Virgen del Rocío, Sevilla, Spain

P1-14-16

Risk of Distant Recurrence in T1aN0 HER2-Positive Breast Cancer: A Retrospective Analysis

Rohan U. Patwardhan, Mayo Clinic, Phoenix, AZ

P1-14-17

Pathologic Complete Response and Survival in Non-Metastatic Inflammatory Versus Non-Inflammatory Breast Cancer Across Breast Cancer Subtypes

Maeve A. Hennessy, University of Chicago Medicine, Chicago, IL

P1-14-18

Racial and Ethnic Differences in Cardiovascular Toxicity Among Women Receiving CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer: A TriNetX Analysis

Mandeep Singh, University of Rochester Medical Center, Rochester, NY

P1-14-19

The association between modifiable risk factors and bone marrow disseminated tumor cells in patients with early-stage breast cancer

C. Natasha Kwendakwema, University of Washington/Fred Hutch Cancer Center, Seattle, WA

P1-14-20

Staging and follow-up of patients with early and metastatic invasive lobular carcinoma: insights from a worldwide clinician survey

Karen Van Baelen, Catholic University Leuven, Leuven, Belgium

P1-14-21

Post-treatment cardiac outcomes in germline BRCA1 pathogenic variant carriers with early-stage breast cancer: a retrospective cohort study

Elias Tayar, University of Houston/HCA Clear Lake, Webster, TX

P1-14-22

Clinicopathologic Predictors of Node-Negative Disease to Support SLNB Omission in cT1N0 Breast Cancer

Máté Iványi, University Of Szeged, Szeged, Hungary

P1-14-23

Five year patient-reported outcomes of BOOG 2013-08 evaluating omission of sentinel lymph node biopsy: impact of personality traits on health-related quality of life in early breast cancer treated with breast conserving therapy

Martine Moossdorff, Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands

P1-14-24

Emotional Awareness Predicts Longer Survival after Breast Cancer Diagnosis

Karen L. Weihs, The University of Arizona, Tucson, AZ

P1-14-25

Clinicopathological Characteristics and Survival Outcomes of Solid Papillary Carcinoma Versus Ductal Carcinoma of the Breast: A Population-Based Study with Propensity Score Matching and Competing Risk Analysis

Wei Wang, Shanghai General Hospital, Shanghai, China

P1-14-26

Baseline Disease Burden Remains Prognostic Despite Pathologic Complete Response (pCR) After Neoadjuvant Therapy in Early-Stage Breast Cancer

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P1-14-27

Use of Telehealth for the Management of Endocrine Therapy in Veterans with DCIS

Sita Bushan, Baylor College of Medicine, Houston, TX

P1-14-28

Dual CXCR4/FAP-targeted NIR-II fluorescence imaging for margin assessment in breast conserving surgery

Ting-Wen Kuo, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China., Xiamen, China

P1-14-29

Rare Tumors of the Breast: Lymphoid, Neuroendocrine and Mesenchymal Neoplasms – A Multicenter Retrospective Cohort Study

muzeyyen asli ergozoglu, cukurova university, ADANA, Turkey

P1-14-30

Association of obesity with post-treatment cardiovascular outcomes in germline BRCA1 pathogenic variant carriers with early-stage breast cancer

Elias Tayar, HCA Healthcare Clear Lake, Webster, TX

P1-15-01

Clinical Relevance of Established Post-Neoadjuvant Prognostic Factors in a Predominantly Stage III Mexican Breast Cancer Cohort

Mayte Pacheco, National Institute of Cancerology, Mexico City, Mexico

P1-15-02

Adjuvant Zoledronic Acid Reduces Recurrence and Improves Disease-Free Survival in Breast Malignant Phyllodes Tumors via Suppressing CREB1-PLK1: A Phase 2 Trial

Yan Nie, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

P1-15-03

Hla-dr expression on cd8+ effector memory t cells predicts response to neoadjuvant chemotherapy in hormone receptor-positive early breast cancer.

Cristina Arqueros Nunez, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

P1-15-04

Response to Neoadjuvant Chemotherapy versus Endocrine Therapy in Invasive Lobular Breast Cancer: A Real-World Analysis of Predictors and Outcomes

Aleksandra Zolotukhina, NMRC of Oncology named after N.N. Petrov, Saint Petersburg, Russian Federation

P1-15-05

Enhanced Survival from Anthracycline Chemotherapy in Metaplastic Breast Cancer: A Retrospective Study of 25 China Centers

Can Zhou, First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China

P1-15-06

Prognostic significance of the red blood cell-balanced immuno-inflammation (RBI) score in primary invasive breast cancer: a large-scale, two-center retrospective study

Yuan Feng, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

P1-15-07

Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection After Neoadjuvant Chemotherapy in Breast Cancer: A Systemic Review and Meta Analysis

Noor Khalid, Simmons Cancer Center, Southern Illinois University School of Medicine, Springfield, IL

P1-15-08

Surgical Management of Breast Cancer in Women Aged 70 Years and Older: Utilization Trends and Association with Overall Survival

Cara Coleman, Medical University of South Carolina, Charleston, SC

P1-15-09

Reproducibility of Pathologist-read and AI-assisted ER scoring in ER-low breast cancer

Sanna Steen, Karolinska Institutet, Stockholm, Sweden

P1-15-10

Multi‑Cycle Safety and Hematologic Outcomes of Same‑Day Eflapegrastim With Docetaxel and Cyclophosphamide in Early‑Stage Breast Cancer

Howard Franklin, Assertio Holdings, Inc., Lake Forest, IL

P1-15-11

Association of PD-L1 Expression and Stromal Tumor-Infiltrating Lymphocytes with Clinical and Pathological Features of Early-Stage Metaplastic Breast Cancer: A Retrospective Single-Institution Experience

Ashley Matusz-Fisher, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Atrium Health Levine Cancer, Wake Forest University School of Medicine, Charlotte, NC

P1-15-12

Surrogate Endpoints in Early Breast Cancer a Delphi panel study in Europe, USA, and Canada

Alberto Zambelli, Università degli Studi di Milano Bicocca, milan, Italy

P1-15-13

Prognostic value of pathologic complete response across neoadjuvant treatments and breast cancer subtypes

Marco Mariani, Vita-Salute San Raffaele University, Milan, Italy

P1-15-14

Stage-specific incidence and treatment for ipsilateral invasive breast cancer after Ductal Carcinoma in Situ: a population-based cohort study of 23,649 women

Margot Nieberg, Netherlands Cancer Institute, Amsterdam, Netherlands

P1-15-16

Correlation and Categorical Agreement Between Breast Cancer Index Prognostic Score and Oncotype DX Recurrence Score in Hormone Receptor Positive Breast Cancer – A Cohort Analsysis

Safwan Muhammad, Bayhealth Hospital, Dover, DE

P1-15-17

A trial-based cost-effectiveness analysis of omitting the sentinel lymph node biopsy in early-stage breast cancer patients treated with breast-conserving therapy: Results from the BOOG 2013-08 trial

Martine Moossdorff, Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands

P1-15-18

Clinical characteristics and disease-free survival outcomes in young patients with early-stage breast cancer: A retrospective study in Vietnam

Ha B Tran, Danang Oncology Hospital, Danang, Viet Nam

P1-15-19

Impact of Obesity on Survival Outcomes in Young Women With Early Breast Cancer

Simona Borstnar, Institute of Oncology Ljubljana, Ljubljana, Slovenia

P1-15-20

Real-world Surgical Utilization Trends, Disparities, and Reasons for Omission in Ductal Carcinoma in Situ: A 313,048-Patient Analysis

Cara Coleman, Medical University of South Carolina, Charleston, SC

P1-15-21

Pathologic Complete Response in the Dual Anti-HER2 Therapy Era and Late Recurrence Analysis After Endocrine Therapy in Hormone Receptor-Positive/HER2-Positive Breast Cancer

Ee Jin Kim, Asan medical center, Seoul, Korea, Republic of

P1-12-01

The Association between Food Swamps and Postmenopausal Breast Cancer Mortality in Georgia and South Carolina

Malcolm Bevel, Augusta University, Augusta, GA

P1-12-02

Racial and Ethnic Disparities in 5-Year Cause-Specific Survival Among Early-Onset Breast Cancer Patients: A Population-Based Analysis of the SEER Database

Mohammad Yousef Elimat, cairo university, giza, Egypt

P1-12-03

Contemporary breast cancer survival by molecular subtype and diagnosis period across Asian American groups and pooled Native Hawaiian/Pacific Islander women: A population-based analysis

Noor Khalid, Simmons Cancer Center, Southern Illinois University School of Medicine, Springfield, IL

P1-12-04

Beyond awareness: perceived comparative risk drives intentions to reduce alcohol use for breast cancer prevention among U.S. women

Dipali V Rinker, University of Houston, Houston, TX

P1-12-05

Global Variation in Alcohol-Attributable Breast Cancer Burden by World Bank Income Group: A GLOBOCAN 2022 Ecological Analysis

Danielle Laperche-Santos, Oncoclínicas, Goiânia, Brazil

P1-12-06

Three Paths: A Narrative Educational Intervention to Encourage Timely Evaluation of Breast Symptoms

Danna Remen, Global Oncology, Oakland, CA

P1-12-07

Clinical Presentation, Tumor Characteristics, and Outcomes of Gestational Breast Cancer: The EMBARCAM study (GEICAM/2017-07)

Ángel Guerrero, Instituto Valenciano de Oncología, Valencia, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain

P1-12-08

Breast cancer risk among survivors of hematopoietic stem cell transplant with or without total body irradiation: A population-based analysis

Helena J. Janse van Rensburg, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

P1-12-09

Temporal Improvements in Breast Cancer-Specific Mortality Differ by Age and Tumor Subtype: A Population-Based Analysis of 617,911 Women Diagnosed Between 2010 and 2023.

Jose P. Leone, Dana-Farber Cancer Institute, Boston, MA

P1-12-10

Probiotic use and breast cancer risk: evidence from all of us

Yangbo Sun, UTHSC, MEMPHIS, TN

P1-12-11

A population-based analysis of breast cancer screening practices after hematopoietic stem cell transplant with or without total body irradiation

Helena J. Janse van Rensburg, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

P1-12-12

The Age-Specific Burden of Metabolic and Lifestyle Risk Factors concerning Breast Cancer within U.S. Women: A Global Burden of Disease Analysis, 1990-2023

Pavani Chalasani, The George Washington Cancer Center, Washington, DC

P1-12-13

Pathology of pregnancy, gestational diabetes and preeclampsia, affect clinical biomarkers and subtype breast cancer after

Maxim Izquierdo, Hospital Universitario Dexeus, Barcelona, Spain

P1-12-15

Decoupling from Phenotypes: Paradoxical GLP-1/Tirzepatide Surge in Non-Obese, Non-Diabetic Breast Cancer

Kian-Hwee Chong, Taipei Tzu Chi Hospital, New Taipei City, Taiwan

P1-12-16

Accrual Patterns to the Alliance Guiding Endocrine Therapy Success with Empowerment and Technology (GETSET) Trial Using Strategic Staged Closure (A191901)

Katherine E. Reeder-Hayes, University of North Carolina at Chapel Hill, Chapel Hill, NC

P1-12-17

Dynamic Measures of Disease Trajectory Outperform Comorbidity in Predicting Outcomes in Metastatic Breast Cancer

Abbey J Kaler, The University of Texas MD Anderson Cancer Center, Houston, TX

P1-12-18

Metabolomic Correlates of Visceral and Subcutaneous Adiposity: A Pilot Study among African-American and White Breast Cancer Survivors

Elinor Laffargue, University of Maryland School of Public Health, College Park, MD

P1-12-19

Geographic disparities in breast cancer incidence, mortality, and late-stage diagnosis across rural and urban areas of Kentucky Appalachia and Mississippi Delta regions of Kentucky and Louisiana

Ruth J Larson, The Ohio State University, Columbus, OH

P1-12-20

Breast cancer risk stratification by estrogen receptor subtype among Ghanaian women

Qinran Liu, American Cancer Society, Atlanta, GA

P1-12-21

Development and validation of a BReast cAncer Stigma Scale (BRASS) to assess stigma among the general population and healthcare workers

Marwatunnisa Al Mubarokah, Dana-Farber Cancer Institute, Boston, MA

P1-12-22

Burden of mortality due to brain metastases secondary to breast cancer in the United States: a population-based study, 1999-2025

Shreya Ghanshyam Patel, Lakeland Regional Health, Lakeland, FL

P1-12-23

Duration-dependent impact of longstanding obesity on breast cancer incidence: a real-world Trinetx cohort study

Yao-Jen Chang, Taipei Tzu Chi Hospital, New Taipei City, Taiwan

P1-3-28

The prognostic and predictive role of estrogen receptor (ER) expression in ductal carcinoma in situ (DCIS): a systematic review and meta-analysis

Abhisekh Chatterjee, Imperial College London, London, United Kingdom

P1-12-24

From Tobacco to Alcohol: Shifting Behavioral Drivers of Breast Cancer Burden Among U.S. Women, 1990-2023

Pavani Chalasani, The George Washington Cancer Center, Washington, DC